A powerful match - celebrating three years of Croda Pharma and Avanti
Today marks three years since we acquired Avanti Polar Lipids. During the COVID-19 pandemic, it became clear that the combination of Avanti's lipid expertise and our manufacturing scale-up capability could enable us to deliver the impossible.
Working hand in hand, Avanti’s know-how and technology have proven to be highly complementary to our capability in drug delivery systems, vaccine adjuvants and immunotherapy.
Working hand in hand, Avanti’s know-how and technology have proven to be highly complementary to our capability in drug delivery systems, vaccine adjuvants and immunotherapy.
Many staff joined the Croda family along with the Avanti acquisition, here are some of their stories:
Ethan Cagle
Safety Health and Environment Department
"Prior to the acquisition by Croda, my current position did not exist. The acquisition by Croda has allowed me to work in a field that I have always been interested in and to use my background to help make sure everyone goes home just as good or better than when they came to work. I really enjoy getting to work with all levels of the organization at the site and the interactions that the SHE group has within the region and globally. It is also really exciting to see the impact that Croda Pharma products have on the lives of the end users. We really do practice Smart science to improve lives™. There has been a significant shift in the culture of the site that really pushes a focus on the health and safety of the employee by increasing the overall safety of our processes".
"After the acquisition, Croda invested heavily in the cGMP Manufacturing Facility essentially doubling the overall manufacturing space. This has lead to expansion of the process development group both in personnel and laboratory space, allowing us to increase development and optimization capacities. Our products are used in therapeutics from early phase clinical applications to commercial pharmaceuticals. It is extremely fulfilling to work on projects every day that have potential to improve the lives of so many people. Since the acquisition there has been significant investment in the future of Avanti products. From the initial transfer and scale-up of COVID vaccine raw materials to planned scale-ups of legacy products, the large-scale manufacturing capacities of other Croda sites around the world greatly expand the potential impact of Avanti technology".
Justin Martin, Lead Development Scientist in the cGMP Process Development Group
Check out Justin's story:
.png?la=es-MX&hash=6AD59F44068C2BFCC72B3D624CE59B07)
Learn how we delivered the impossible
During the pandemic of 2020, it became clear that the combination of Avanti’s lipid expertise and Croda’s manufacturing and scale-up capability could enable a faster response to the Covid-19 pandemic. Leveraging this, and scaling at unprecedented speed, we became the first company to supply the essential lipid ingredients for a COVID-19 vaccine at scale, globally.
Decades of driving biopharma forward
Explore related content:
Strengthening Life Sciences with the acquisition of Avanti Polar Lipids
13 August 2020: A leader in drug delivery systems for next generation pharmaceuticals, the acquisition more than doubles Croda’s research and development (R&D) capability in drug delivery.
Croda announces two new partnerships to drive sustainable delivery systems for the pharmaceutical industry
19 May 2023: Croda International Plc (Croda) today announced that it has signed two new partnership agreements that will help the pharmaceutical industry move towards a more sustainable supply chain for vaccine adjuvants.
Nucleic Acid Delivery
We develop and manufacture innovative lipids of unparalleled purity to solve the stability and delivery issues associated with mRNA for use in vaccines and next-generation therapeutics